What Do Analysts Suggest For Gilead Sciences Inc. (GILD)

Share

Regent Investment Management Llc sold 12,900 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%. The stock declined 0.12% or $0.1 reaching $81.21 on the news. About 227,767 shares traded.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. It has underperformed by 38.50% the S&P500.

Andrew Weiss increased its stake in Seabridge Gold Inc (SA) by 488.24% based on its latest 2017Q2 regulatory filing with the SEC. Comgest Glob Investors Sas invested in 2.92% or 1.71M shares. The Tower Research Capital Llc Trc holds 70 shares with $6,000 value, down from 5,505 last quarter. Microsoft Corp now has $597.62 billion valuation. Creative Planning invested in 150,900 shares or 0.03% of the stock. Cognios Ltd Liability Co accumulated 48,210 shares. Skyworks Solutions Inc (NASDAQ:SWKS) has risen 65.40% since October 13, 2016 and is uptrending. It has outperformed by 130.42% the S&P500. Centene Corporation had 42 analyst reports since July 22, 2015 according to SRatingsIntel. Bank of America has "Neutral" rating and $107.0 target. The firm has "Buy" rating by Tigress Financial given on Monday, January 23. The firm earned "Buy" rating on Saturday, August 29 by JP Morgan. The stock has "Buy" rating by Berenberg on Thursday, September 22. The firm has "Sell" rating by Citigroup given on Wednesday, July 26. Leerink Swann has "Market Perform" rating and $89 target. They expect $2.07 EPS, down 23.33% or $0.63 from last year's $2.7 per share. AFAM's profit will be $7.68 million for 21.11 P/E if the $0.55 EPS becomes a reality. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts' consensus estimates of $2.11 by $0.45.

Since May 1, 2017, it had 0 buys, and 5 insider sales for $11.13 million activity. On Monday, June 12 the insider GEPHARDT Richard A sold $336,603. (NASDAQ:GILD) on Monday, May 1.

Investors sentiment decreased to 1.21 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. Cleararc Capital invested in 32,045 shares. 29 funds opened positions while 75 raised stakes. Trexquant Lp reported 4,100 shares. Seabridge Gold, Inc. (USA) (NYSE:SA) has declined 18.80% since October 13, 2016 and is downtrending. Fil Ltd stated it has 0.04% of its portfolio in Centene Corp (NYSE:CNC). Hyman Charles D owns 3,064 shares or 0.03% of their United States portfolio. The Rhode Island-based Amica Pension Fund Board Of Trustees has invested 0.54% in the stock. Dupont reported 68,205 shares or 0.12% of all its holdings. 16,674 were accumulated by Peddock Capital Advsr Ltd Liability Corp. Meristem Llp reported 30,810 shares. With an institutional ownership near 71.3%, it carries an earnings per share ratio of 0.37.

Robecosam Ag decreased Solaredge Technologies Inc stake by 20,000 shares to 330,000 valued at $6.65M in 2017Q2. Ross Stores Inc (NASDAQ:ROST) was raised too. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Therefore 82% are positive. Analysts reported that the Price Target for Gilead Sciences Inc. might touch $96 high while the Average Price Target and Low price Target is $84.29 and $65 respectively. As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. The rating was maintained by Piper Jaffray on Tuesday, July 25 with "Buy".

The 14-day ADX for Carbon Sciences Inc (CABN) is now 16.47.

Capital World Investors Invests $9.65 Million in Ares Management LP (ARES)
Omers Administration Corp decreased Slm Corp (NASDAQ:SLM) stake by 35,800 shares to 34,600 valued at $398,000 in 2017Q2. California Public Employees Retirement System increased Exelon Corp (EXC) stake by 1.16% reported in 2017Q2 SEC filing.

Among 34 analysts covering Microsoft Corporation (NASDAQ:MSFT), 28 have Buy rating, 2 Sell and 4 Hold. Oppenheimer has "Outperform" rating and $120 target. The rating was maintained by RBC Capital Markets on Wednesday, November 2 with "Outperform". On Monday, June 26 the stock rating was maintained by Jefferies with "Buy". As per Tuesday, September 6, the company rating was upgraded by Jefferies.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on November, 7.

Investors sentiment decreased to 0.82 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. It dived, as 39 investors sold MSFT shares while 982 reduced holdings. 110 funds opened positions while 462 raised stakes. Nomura Asset Management Communications Ltd reported 2.30 million shares or 2.13% of all its holdings. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the first quarter worth $143,000. (NASDAQ:GILD) for 78,909 shares. The Herndon Capital Management Llc holds 293,842 shares with $20.80M value, down from 313,915 last quarter. Indiana Tru And Invest Mgmt reported 19,541 shares. Hills Savings Bank And Trust reported 18,254 shares stake. (NASDAQ:GILD). Hallmark Capital Mngmt Inc holds 0.22% of its portfolio in Gilead Sciences, Inc. Davis R M stated it has 0.05% in Gilead Sciences, Inc.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. (NASDAQ:GILD). Lingohr And Partner Asset Mngmt Gmbh invested in 20,573 shares. 146.46 million shares or 0.78% less from 147.62 million shares in 2017Q1 were reported. Clean Yield Grp has 51,833 shares for 1.53% of their portfolio. Orleans Mgmt La reported 10,429 shares. $668,667 worth of Gilead Sciences, Inc. (NASDAQ:GILD). Baldwin Brothers Ma reported 280 shares.

Since May 1, 2017, it had 0 insider purchases, and 5 selling transactions for $11.13 million activity. MARTIN JOHN C also sold $5.01 million worth of Gilead Sciences, Inc. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Monday, October 2nd. Gilead Sciences, Inc. The firm has a 50-day moving average price of $82.03 and a 200-day moving average price of $72.08.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Share